<DOC>
	<DOCNO>NCT00030615</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine treating patient advance solid tumor respond previous treatment . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>Decitabine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose decitabine patient advance solid tumor . II . Determine toxic effect drug patient . III . Determine dose drug biologic activity patient . IV . Determine pharmacokinetics drug patient . V. Determine clinical response drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive decitabine IV 30 minute day 1-5 weekly 4 week . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos decitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis advance metastatic solid tumor standard therapy fail , include , limited following : Stage III IV melanoma Mucosal melanoma allow No resectable stage III melanoma Bladder cancer Breast cancer No active symptomatic CNS disease No radiographically evident cerebral edema Hormone receptor status : Not specify Male female Performance status ECOG 01 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm^3 WBC least 3,500/mm^3 Absolute granulocyte count least 1,500/mm^3 No coagulation disorder Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Hepatitis B surface antigen negative Hepatitis C antibody negative Creatinine great 1.5 time ULN No major cardiovascular system illness No major respiratory system illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No major systemic infection At least 1 month since prior radiotherapy At least 1 month since prior anticancer therapy adjuvant therapy No experimental treatment within 30 day prior , , 30 day study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>